Dupixent® (dupilumab) Approved by FDA as the First and

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...

Related Keywords

Japan , Paris , France General , France , Regeneron , Georged Yancopoulos , Naimish Patel , Regeneron Velocimmune , Prnewswire Regeneron Pharmaceuticals Inc , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Drug Administration , Dupilumab Development Program , Regeneron Velocimmune Technology , Nasdaq , Teva Pharmaceutical Industries Ltd , Exchange Commission , European Union , European Medicines Agency , Head Of Global Development , Euronext , Priority Review , Chief Scientific Officer , Global Development , Dupixent Prurigo Nodularis , Worst Itch Numeric Rating Scale , Global Assessment , Chief Scientific Officer George , Nasal Polyposis , Regeneron Genetics , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Nc , Health Care Amp Hospitals , Pharmaceuticals , Medical Pharmaceuticals , Fda Approval ,